BARD1 and triple-negative breast carcinoma: These results are consistent with clinical suspicion, as on the one hand, the variant appears to cosegregate with the phenotype and, on the other hand, pathogenic variants in the BARD1 gene have been associated with an increased relative risk of triple negative breast cancer [13, 14].